参考资料 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data.https://index.mirasmart.com/AAN2024/PDFfiles/AAN2024-005124.html 编辑| Arzt 仅供学习交流! 授权转载及...
CLINICAL trialsINTERFERONSOpen-label extension (OLE) studies help inform long-term safety and efficacy of disease-modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase 2 trial on the longest follow-up to date of ocrelizumab-treated patients with relapsing鈥搑...
Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America 3.2.6Ocrelizumab Based on results from rituximab, a humanised anti-B lymphocytemonoclonal antibody,ocrelizumab, was evaluated in patients with PPMS. In this phase 3 clinical trial, 732 pat...
I have several concerns about the clinical trial by Ludwig Kappos and colleagues (Nov 19, p 1779) of the monoclonal antibody ocrelizumab in relapsing-remitting multiple sclerosis. First, I disagree that ocrelizumab has a benign safety profile. The death of a patient in the high-dose group was...
Pineda E, Sheinson D, Ng C, Bonine N, Pardo G. Adherence and persistence to disease-modifying therapies for multiple sclerosis and their impact on clinical and economic outcomes in a US claims database. Poster presented at: 73rd AAN Annual Meeting; April 17-22, 2021; virtual....
A subcutaneous injection of ocrelizumab was markedly effective at suppressing brain lesions in patients with multiple sclerosis, according to data from a phase 3 trial. Ocrelizumab (Ocrevus; Roche) subcutaneous (SC) injection was found to effectively suppress brain lesions in patients with...
The respective effectiveness of ocrelizumab and rituximab in RRMS has previously been studied in 2 randomized clinical trials. In the Helping to Evaluate Rituxan in Relapsing-Remitting Multiple Sclerosis (HERMES) phase 2 rituximab trial, patients were treated with 2 doses of rituximab, 1...
an article published Online First in The Lancet a phase 2 randomized, open label, placebo-controlled trial demonstrated the new monoclonal antibody ocrelizumab successfully targets B cells, immune cells implicated in , and rapidly reduces disease-related, inflammatory brain lesions and clinical attacks....
San Diego, California — Long-term follow-up of patients with multiple sclerosis (MS) in the phase 2 trial of ocrelizumab suggest that the drug continues to be effective for up to 18 months after the last dose, with no new safety concerns identified. ...
“a proprietary clinical gold standard” through 2018, according to Decision Resources. “Surveyed neurologists told us that a drug’s effect on long-term disability progression is the attribute that most influences their prescribing decisions in chronic progressive multiple sclerosis,” reports Bethany ...